Lower low-lipoprotein cholesterol level at the time of acute myocardial infarction is associated with increased cardiovascular events
Abstract Body (Do not enter title and authors here): Abstract Background: Lipid-lowering therapy for patients with acute myocardial infarction (AMI) is highly recommended, however, a paradox may exist where lower low-density lipoprotein cholesterol (LDL-C) levels at myocardial infarction (MI) are associated with poorer prognoses. Aim: To evaluate the association between baseline LDL-C levels and cardiovascular events after MI. Methods: We studied 1,987 consecutive AMI patients who underwent primary percutaneous coronary intervention and who had available data on preprocedural LDL-C between 1999-2015 at Juntendo University Shizuoka Hospital. Patients were divided into quartiles based on their LDL-C levels. The incidence of major adverse cardiac events (MACE), including all-cause death and recurrent MI up to 5-year, were evaluated. Results: Patients in the lowest LDL-C group were older and had higher prevalence of hypertension, diabetes mellitus and chronic kidney disease. During follow-up, 455 (20.9%) MACE were identified. Cumulative incidence of MACE was significantly higher in the lowest LDL-C group than in other groups (p<0.0001, Figure). After adjustment for other risk factors, the lowest LDL-C group had a significantly higher risk of MACE compared with the highest group (hazard ratio, 1.52; 95% confidence interval, 1.11-2.08; p=0.009). On the other hand, no significant difference in cardiovascular risk was found for patients in the highest LDL-C group compared to patients in the second or third groups. Conclusions: Lower LDL-C level was associated with worse clinical outcomes among patients with MI. Patients with lower LDL-C level have a poor prognosis and require more attention.
Onozato, Takuya
( Juntendo university shizuoka hospital
, Izunokuni city
, Shizuoka prefecture
, Japan
)
Wada, Hideki
( Juntendo University Shizuoka Hospital
, Izunokuni Shizuoka
, Japan
)
Abe, Keiki
( Juntendo university shizuoka hospital
, Izunokuni city
, Shizuoka prefecture
, Japan
)
Singh, Yu Suresvar
( Juntendo University
, Izunokuni
, Japan
)
Shitara, Jun
( Juntendo university shizuoka hospital
, Izunokuni city
, Shizuoka prefecture
, Japan
)
Suwa, Satoru
( Juntendo university shizuoka hospital
, Izunokuni city
, Shizuoka prefecture
, Japan
)
Miyauchi, Katsumi
( Juntendo University
, Tokyo
, Japan
)
Minamino, Tohru
( JUNTENDO UNIVERSITY
, Tokyo
, Japan
)
Author Disclosures:
Takuya Onozato:DO NOT have relevant financial relationships
| Hideki Wada:DO NOT have relevant financial relationships
| Manabu Ogita:No Answer
| Keiki Abe:No Answer
| Yu Suresvar Singh:No Answer
| Jun Shitara:No Answer
| Satoru Suwa:No Answer
| Katsumi Miyauchi:No Answer
| Tohru Minamino:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Boehringer Ingelheim:Past (completed)
; Research Funding (PI or named investigator):Eizai:Active (exists now)
; Research Funding (PI or named investigator):Kirin:Past (completed)
; Research Funding (PI or named investigator):Teijin:Past (completed)
; Research Funding (PI or named investigator):Roche:Active (exists now)
; Research Funding (PI or named investigator):Kowa:Past (completed)
; Research Funding (PI or named investigator):Otsuka:Past (completed)
; Research Funding (PI or named investigator):Sumitomo:Past (completed)
; Research Funding (PI or named investigator):Boston:Active (exists now)
; Advisor:Fukudadenshi:Active (exists now)
; Research Funding (PI or named investigator):Abbott:Active (exists now)
; Research Funding (PI or named investigator):Biotronik:Active (exists now)
; Research Funding (PI or named investigator):Medtronic:Active (exists now)